Indian team develops new drug distribution system to treat rheumatoid arthritis
The new treatment targets inflammation directly within the joints so that therapeutic agents are issued only when needed.
In short
- Traditional approach carries the risk of significant side effects
- It requires frequent doses due to rapid withdrawal of drugs
- The team has developed a smart system that directly responds to biochemical signals
A team of Indian researchers has developed an innovative “self-active” drug distribution system that can change the treatment of rheumatism (RA).
Rheumation (RA) is a chronic autoimmune disease that mainly affects joints, causing pain, swelling, hardness and low mobility. Unlike osteoarthritis, which results in wear and tear, RA occurs when the immune system accidentally attacks synovium – lining of joints – leading to swelling and joint damage over time.
The new treatment targets inflammation directly within the joints so that therapeutic agents are issued only when needed. The approach is different from traditional remedies that often depend on systemic medicine administration.
Traditional approach not only carries the risk of important side effects, but also requires frequent doses due to rapid extraction of drugs from inflammatory joints and is a challenge for long -lasting, localized relief.
Researchers at the Institute of Nano Science and Technology (Inst) Mohali have developed a smart system that directly responds to biochemical signals in the synovial environment.
“The system uses specifically designed microcefers that have been loaded with methotrexate, usually an anti-romatic drug. Engineering is done to leave, reduce side effects and improve medical results, “Ministry of Science and Science Ministry and Science and Ministry of Science and Ministry of Science said in a release.
Dr. The team headed by Rahul Kumar Verma developed a emotionalization of polymer-lipid hybrid micro-compositions, where lipid component (soy lecithin) ensures high drug encalsuation efficiency, and provides accountability to a polymer component (gelatin) matrix metaloproteinis (MMP) Does. , The system takes advantage of the unique biochemical signals present in inflammatory synovial microelements.
The study published in Journal Biometric Advance provides a safe, more effective option for current RA remedies by eliminating the need for frequent drug injections and reducing systemic poisoning.
The system increases the effectiveness of the drug by improving bioavailability and retention in affected joints, which provides prolonged relief with low doses.
